Teeth grinding

Individual cost plan after consultation

Teeth Grinding — nightly clenching that strains teeth, jaw joint and chewing muscle, often with morning headache. Botulinum toxin type A injected into the masseter muscle reduces the force of clenching; chewing itself stays possible. Evidence shows muscle activity drops measurably, while felt pain relief varies across studies — both sides are discussed openly. Off-label use in Germany, based on individual benefit-risk assessment. Treatment by a board-certified anesthesiologist.

Bruxism · Masseter muscle · Tension & pain

Teeth Grinding

Nightly teeth grinding strains teeth, jaw joint and muscle — and often the head. Botulinum toxin type A takes strength away from the chewing muscle; chewing itself stays possible. The evidence shows nightly muscle activity drops measurably; whether you feel that yourself is less clearly established. Both sides of the story are on this page.

Duration of effect3–4 monthsClinical experience value. In the only cross-over study, the EMG effect was no longer detectable after 12 weeks.

Treatment time15–20 minBoth sides, a few points per muscle.

Onset1–2 weeksMaximum after 4 weeks. Follow-up after 4–6 weeks.

Book a consultation

In short

Sleep bruxism is rhythmic chewing-muscle activity during sleep — measurable on muscle EMG, linked to stress regulation and sleep architecture. The consequences build up over weeks: pressure pain in the chewing muscle, morning headache, worn enamel edges, a thickening chewing muscle. A bite splint protects the teeth but does not address the muscle. Botulinum toxin type A blocks nerve-to-muscle signal transmission at the chewing muscle — the involuntary constant tension eases while voluntary chewing strength remains. The application is not approved in Germany (off-label) and is carried out medically after a benefit-risk assessment. It is one building block in a concept of splint, stress management, manual medicine and sleep hygiene — not a replacement for them.

Dr. Thomas Ackermann's practice · Methodological stance

A treatment is only good once it fits the right patient. The first questions in the consultation are never about the active ingredient — they are about the findings, the contributing factors, the life situation. Botulinum toxin takes strength from the muscle, not the trigger. Someone who grinds from tension keeps grinding — just with less force reaching the teeth and jaw joint.

— Dr. med. Thomas Ackermann · Board-certified anesthesiologist

Mechanism · The muscle works, the head pays

What happens at night

A note on terminology: Many patients search for “Botox” — a brand name of one single product that has become a colloquial umbrella term. The active substance is botulinum toxin type A, contained in several licensed medicinal products. All of them are prescription-only and are injected exclusively by the physician after a medical examination. This page uses the substance name throughout — it refers to the same treatment commonly known as a Botox treatment.

Structure	Role in bruxism	During treatment
Masseter muscle	Main force in clenching and grinding; thickens under constant load (hypertrophy)	Target muscle — bilateral, several points in the lower, thicker portion
Temporalis muscle	Second chewing muscle; source of temple-focused headaches	Co-treated when involved — in Cruse's study the combination worked more strongly
Medial pterygoid muscle	Third chewing muscle, not palpable from outside	Only with a pronounced finding, generally not treated
Risorius and zygomaticus muscles	Lie in front of the chewing muscle	Must be avoided — placed too far forward, they change the smile
Parotid gland	Lies over the rear of the chewing muscle	Keep a safe distance; palpate before every injection

Botulinum toxin type A acts at the neuromuscular junction: it locally blocks the release of acetylcholine. The muscle is not paralyzed, only dampened in its maximum force. With a chronically thickened muscle, muscle mass decreases after repeated treatment — a side effect, not the goal, and not a cosmetic indication.

The evidence · What is established and what is not

Reading the evidence honestly

The evidence on botulinum toxin for bruxism has grown over the last fifteen years. It shows a consistent direction — and clear limits that are missing from most websites.

Question	What the studies show	What they do not show
Does nightly muscle activity drop?	Yes. Double-blind cross-over study (Cruse 2022): bruxism index on EMG significantly lower after 4 weeks than under placebo (p = 0.003), stronger with higher dose and more muscles treated	After 12 weeks the difference was no longer detectable
Do patients feel a difference?	In 3 of 12 randomized studies in Yacoub 2025's review, pain dropped measurably	In the cross-over study, there was no difference at any time point in headache, pain or perceived grinding versus placebo
How good are the reviews?	14 systematic reviews find effects on pain (10), grinding frequency (7) and bite force (5)	All 14 were rated methodologically "critically low" or "low" (AMSTAR-2, Coelho 2025) — definitive conclusions are not possible
What is the best treatment?	Meta-analysis across 22 studies (Assiri 2025): splints, botulinum toxin and biofeedback each work on partial aspects	No single method works for everyone — the authors recommend a multimodal approach

All studies individually verified in PubMed, sources with PMID at the bottom of the page. The direction is consistent, the quality heterogeneous. That is why the medical judgment in the individual case remains the decisive step — no study replaces it.

Safety profile

What you can realistically expect

Observation	Frequency	Duration
A feeling of weakness when chewing hard food	common in the first weeks — the sign that the effect has started	1–2 weeks, then adaptation
Bruising, tenderness at the injection sites	common	3–7 days
No noticeable difference despite a measurable EMG effect	possible — in the cross-over study, participants reported no difference from placebo	—
Altered smile, one corner of the mouth lifting less	rare — with injection placed too far forward or too superficially	until the effect wears off, 6–12 weeks
A narrower-looking face (reduced muscle mass)	regular with repeated treatment of a thickened muscle	persists as long as treatment continues
Headache after treatment	occasional	1–2 days

No serious adverse events were described in the available randomized studies; Cruse 2022 reports mild, transient effects in 5 of 22 participants. General safety profile per Brin et al. 2009. More detail in the safety overview.

Common reasons patients come in

Does this sound familiar?

"I wake up with jaw pain and a headache"

The muscle has worked all night. Morning pressure pain in the chewing muscle and headache at the temples and back of the neck are the typical pattern. If the splint protects the teeth but the pain remains, the muscle is the target.

"My dentist says I grind — and fits a splint"

That is correct and remains the first step. Dentists recognize bruxism but do not inject botulinum toxin; neurologists treat headache, not the chewing muscle. Patients who want both considered together find few places that offer it — which is why patients from Forchheim, Höchstadt, Neustadt and Bamberg come to Herzogenaurach.

"My face has gotten wider at the bottom"

A muscle that works against resistance for years grows. Some patients come in for that reason — not the pain, but the contour. Both belong together; but not every wider facial shape comes from the chewing muscle. Bone, fat and skin play a role too. That is shown by the physical exam, not a photo.

Important to know

What botulinum toxin treatment for bruxism is not

Not a replacement for the bite splint. The splint mechanically protects the tooth structure — botulinum toxin cannot do that. It reduces the force of clenching. Dental care continues alongside it.
Not a treatment for the trigger. Stress, sleep quality, breathing during sleep and medications can sustain bruxism. Botulinum toxin dampens the consequence, not the cause — which is why these factors belong in the same conversation.
Not a treatment with a reliably noticeable effect. Muscle activity drops measurably; whether you feel less pain is inconsistent across studies. Anyone who notices no difference after four to six weeks does not repeat it — we discuss this beforehand.
Not an approved application. Botulinum toxin type A is not approved for bruxism in Germany (off-label). Treatment is based on the evidence, following an individual benefit-risk assessment, with written and verbal disclosure per §630e of the German Civil Code. Statutory health insurers do not cover the cost; billing follows private medical fee schedules (GOÄ).

The process

Why this practice

Bruxism rarely occurs on its own.

It is part of a tension pattern that often includes tension headache, migraine, neck tension and sometimes tinnitus. Treatment works best where it addresses not just the chewing muscle but the whole pattern — the 2025 meta-analysis says the same: multimodal rather than a single method.

As a board-certified anesthesiologist with an additional qualification in manual medicine, I bring together pain physiology, muscle tone and autonomic regulation in one consultation. I am a certified member of the DGBT and hold the additional qualification in emergency medicine. When needed, I refer to dentistry, ENT or a sleep lab — and sometimes I advise against treatment.

Related treatments: Chronic migraine with botulinum toxin

How your appointment works

Assessment and pain history. Palpation of both chewing muscles at rest and while clenching, pressure pain, muscle thickness, jaw joint, tooth wear, headache pattern, sleep, stress, medications. Is there already a splint? What has been tried? Please state any blood-thinning medication in advance — and never stop it on your own.
Indication and disclosure. Sensible for sleep bruxism with an objective finding, when the splint alone is not enough — especially with accompanying headache. Not suitable during acute infection, pregnancy, breastfeeding, neuromuscular disease, or known hypersensitivity. Disclosure in writing and verbally, including off-label status.
Dose planning. In the cross-over study, 60 units for both chewing muscles, 90 with the temporalis muscles, 120 with the medial pterygoid muscles — with a stronger effect at higher doses. For a strong muscle I start at the upper end of the chewing-muscle dose range and add the temporalis muscle if it is tender to pressure.
Injection. Several points bilaterally into the lower, thicker portion of the tense chewing muscle — guided by palpation, not a fixed scheme. Distance forward to the risorius muscle, backward to the parotid gland. Ultrasound if muscle thickness is unclear. A few minutes.
Follow-up after 4–6 weeks. Palpation, pressure pain, your own assessment: is the morning pain less, the grinding sound quieter? Residual activity is topped up if needed. Whether to repeat is your decision — muscle activity returns to baseline, not beyond it.

The next step

Findings first. Then the decision.

A sound indication cannot be made from a distance. In the initial consultation we clarify whether the treatment makes sense for you — and what is realistic to expect. Private practice in Herzogenaurach, twelve minutes' drive from Erlangen, thirty from Nuremberg and Fürth.

Book an appointment

Frequently asked questions

About treating teeth grinding

Does this replace my bite splint?

No. The splint mechanically protects the teeth; botulinum toxin reduces the force of clenching. With pronounced bruxism, the combination is often more sensible than either alone. The 2025 meta-analysis across 22 studies reaches the same conclusion: no single method for everyone, but a multimodal approach.

Will I notice a difference?

This is the most honest question — and the answer is: not for certain. Nightly muscle activity drops measurably (EMG). But in the only double-blind cross-over study, participants reported no less headache, pain or grinding than under placebo at any point. In three of twelve randomized studies, pain dropped measurably. Many patients describe less morning tension after 2–4 weeks; the evidence for that is weaker than the EMG effect.

How long does the effect last?

Clinically 3–4 months. Objectively measured, the EMG effect was no longer detectable after 12 weeks in the cross-over study. Anyone promising a longer effect has not read the study.

Can I chew normally afterward?

Yes. The dose dampens overactivity; it does not paralyze the muscle. In the first weeks, hard food — a baguette, chewy meat — can be more effortful. That eases once the remaining muscle strength adjusts.

Will my face get narrower?

With repeated treatment of a thickened chewing muscle, muscle mass decreases and the jaw angle becomes less prominent. This is a side effect of the therapy, not its goal, and not a cosmetic indication. If you specifically do not want this effect, I dose more conservatively — we discuss this beforehand.

Why is this off-label?

Botulinum toxin type A is not approved for bruxism in Germany. Its use rests on the evidence and the physician's benefit-risk assessment. Off-label use is everyday practice in medicine — an established part of pain therapy and anesthesiology. What it means in practice: disclosure noting the off-label status, an individual assessment, and no cost coverage by statutory health insurance.

Is my headache connected to the grinding?

Often. Tension headache at the temples and back of the neck is a typical consequence of nightly chewing-muscle work. Bruxism, tension headache and migraine share biological pathways. If you have several of these complaints, it is worth looking at the overall pattern.

What side effects are possible?

Mostly mild and temporary: tenderness or bruising at the injection sites, a feeling of weakness when chewing, rarely an altered smile if the injection is placed too far forward. No serious adverse events were described in the randomized studies. Discussed thoroughly, in writing and verbally, before every treatment.

What does the treatment cost?

The treatment is a private medical service billed per the German fee schedule (GOÄ). Because this is an off-label application, statutory health insurers do not cover the cost; private insurers decide according to their own tariff. What applies to your treatment is discussed transparently beforehand in the consultation.

Evidence base

What the studies show

Cruse B, Dharmadasa T, White E et al., 2022. Efficacy of botulinum toxin type A in the targeted treatment of sleep bruxism: a double-blind, randomised, placebo-controlled, cross-over study. BMJ Neurol Open 4(2):e000328. PMID 36110927. 22 evaluated participants, three dose groups (60 / 90 / 120 units). Bruxism index on EMG significantly lower after 4 weeks than under placebo (p = 0.003), stronger with higher dose and more muscles; no longer detectable after 12 weeks. No difference in subjective endpoints — headache, pain and grinding — at any time point. 5 mild, transient side effects.
Yacoub S, Ons G, Khemiss M, 2025. Efficacy of botulinum toxin type A in bruxism management: A systematic review. Dent Med Probl 62(1):145–160. PMID 40035138. 12 randomized studies, 10 with low risk of bias. 6 of 12 showed a reduction in muscle activity (EMG), 3 of 12 a reduction in pain. Heterogeneous methodology; long-term data with repeated treatment are missing.
Coelho MS, Oliveira JMD, Polmann H et al., 2025. Botulinum Toxin for Bruxism: An Overview. Toxins (Basel) 17(5):249. PMID 40423331. Overview of 14 systematic reviews: effects on pain (10), grinding frequency (7) and maximum bite force (5). All 14 reviews rated "critically low" or "low" confidence (AMSTAR-2); the authors judge that definitive conclusions are not possible.
Assiri HA, Almuawi LF, Asiri BA et al., 2025. Bruxism treatment outcomes: A systematic review and meta-analysis. Medicine (Baltimore) 104(49):e46247. PMID 41366915. 22 studies from 2019–2024: bite splints reduce nightly muscle activity, botulinum toxin reduces pain and muscle activity, biofeedback offers a non-invasive alternative. No single method is universally effective — the authors recommend a multidisciplinary approach.
Wieckiewicz M, Grychowska N, Zietek M et al., 2017. Evidence to Use Botulinum Toxin Injections in Tension-Type Headache Management: A Systematic Review. Toxins (Basel) 9(11):370. PMID 29140286. 11 cohort studies on tension-type headache, not bruxism: most studies found an association between botulinum toxin and lower pain intensity. Cited here as evidence for the overlap between the chewing muscle and headache.
Brin MF, Boodhoo TI, Pogoda JM et al., 2009. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol 61(6):961–970. PMID 19744746. Pooled safety data from the approved facial regions: no serious treatment-related events, no distant spread.

Study details researched via PubMed. The studies cited describe the state of the published literature and do not establish a claim about the outcome of any individual treatment. Use for bruxism falls outside the drug's regulatory approval.